LALPATHLAB Dr. Lal Path Labs Q4 FY26 results (Jan–Mar 2026) and concall
Dr. Lal Pathlabs reported a strong Q4 and FY26, with double-digit revenue growth driven by volume expansion and strategic initiatives. The company expanded its network, launched new premium services like Sovaaka, and hosted a major medical conference. While Q4 PAT saw a decline due to comparative exceptional items in the prior year, underlying margins remained healthy, and management provided an optimistic outlook for FY27 with early to mid-teens revenue growth and stable margins, supported by continued investments in infrastructure and M&A.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 16.6%, net profit down 15.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 +11% | 660 +11% | 703 +17% |
| EBITDA | 202 | 154 | 169 | 192 | 224 +11% | 179 +16% | 187 +11% |
| Net profit | 131 | 98 | 156 | 134 | 152 +16% | 91 −7% | 132 −15% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
